MELONI, MARIO
 Distribuzione geografica
Continente #
EU - Europa 64.844
NA - Nord America 1.655
AS - Asia 828
SA - Sud America 106
AF - Africa 27
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 1
Totale 67.486
Nazione #
IT - Italia 64.301
US - Stati Uniti d'America 1.598
SG - Singapore 292
CN - Cina 268
SE - Svezia 151
BR - Brasile 96
GB - Regno Unito 88
DE - Germania 75
VN - Vietnam 47
KR - Corea 41
CA - Canada 38
UA - Ucraina 38
FR - Francia 33
FI - Finlandia 32
IN - India 32
NL - Olanda 24
TW - Taiwan 22
AU - Australia 21
HK - Hong Kong 17
IR - Iran 16
ES - Italia 15
TR - Turchia 15
JP - Giappone 14
AT - Austria 13
RO - Romania 13
PH - Filippine 11
IE - Irlanda 10
IQ - Iraq 10
ZA - Sudafrica 10
MX - Messico 9
MY - Malesia 9
CZ - Repubblica Ceca 8
PL - Polonia 7
RU - Federazione Russa 7
SA - Arabia Saudita 7
IL - Israele 6
BE - Belgio 5
EG - Egitto 5
CH - Svizzera 4
ET - Etiopia 4
NZ - Nuova Zelanda 4
RS - Serbia 4
TH - Thailandia 4
AR - Argentina 3
GR - Grecia 3
ID - Indonesia 3
LV - Lettonia 3
PT - Portogallo 3
AE - Emirati Arabi Uniti 2
BB - Barbados 2
BD - Bangladesh 2
CL - Cile 2
JM - Giamaica 2
LB - Libano 2
MA - Marocco 2
PK - Pakistan 2
TN - Tunisia 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EU - Europa 1
GD - Grenada 1
GP - Guadalupe 1
HR - Croazia 1
KE - Kenya 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
MT - Malta 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
VE - Venezuela 1
Totale 67.486
Città #
Cagliari 63.172
Uta 876
Ashburn 175
Chandler 158
Singapore 131
Fairfield 117
Nyköping 97
Dallas 72
Beijing 68
Boardman 64
Woodbridge 60
New York 57
Houston 56
Shanghai 53
Seattle 52
Augusta 51
Wilmington 49
Ann Arbor 48
Los Angeles 40
Cambridge 37
Seoul 37
Dearborn 36
Redwood City 30
Santa Clara 30
Helsinki 23
Jacksonville 20
Ho Chi Minh City 17
London 16
São Paulo 15
Boston 14
The Dalles 14
Buffalo 13
Hanoi 13
Munich 13
Frankfurt am Main 12
Finale Ligure 11
Hefei 11
Atlanta 10
Dublin 10
Glasgow 10
San Mateo 9
Stockholm 9
Syracuse 9
Amsterdam 8
Chicago 8
Denver 8
Hong Kong 8
Phoenix 8
Tramatza 8
Vienna 8
Curitiba 7
Dolianova 7
Guangzhou 7
Milan 7
Nottingham 7
Taipei 7
Tokyo 7
Bacolod City 6
Baghdad 6
Brooklyn 6
Central 6
Changsha 6
Chennai 6
Düsseldorf 6
Falls Church 6
Montreal 6
Mumbai 6
Nanjing 6
Nuremberg 6
Rio de Janeiro 6
San Diego 6
Toronto 6
Brno 5
Bucharest 5
Melbourne 5
Paris 5
Perham 5
Shenyang 5
Sydney 5
Auburn 4
Bangkok 4
Cagayan de Oro 4
Cairo 4
Edgemont 4
Galatina 4
Istanbul 4
Johannesburg 4
Monmouth Junction 4
Richmond 4
San Francisco 4
Sterling 4
Sìnnai 4
Taipei City 4
Uppsala 4
Valencia 4
Villanovafranca 4
Warsaw 4
Wuhan 4
Zhengzhou 4
Beringen 3
Totale 66.128
Nome #
Efficacy and safety of the 5-Hydroxytryptophan on Levodopa-Induced Motor Complications in Parkinson's disease 24.321
C9ORF72 intermediate repeat expansion in patients affected by atypical Parkinsonian syndromes or parkinson’s disease complicated by psychosis or dementia in a Sardinian population 4.249
The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease 4.045
Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Parkinson's disease: a preliminary finding 3.302
Pisa-Like Syndrome Under Baclofen in a Patient With Spastic Hemiparesis due to Ischemic Stroke 3.146
Focal 123I-FP-CIT SPECT abnormality in a patient with midbrain vascular Parkinsonism 3.068
Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding 2.301
Efficacy and Safety of the 5-Hydroxytryptophan on REM Sleep Behavior Disorder in Parkinson's Disease 2.233
Severity of REM sleep without atonia (RSWA) correlates with cognitive functions in patients with REM sleep behaviour disorder (RBD) 2.160
Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Idiopathic Parkinson's disease 2.130
Neuropsychological and behavioral profile of patients with isolated REM sleep behaviour disorders (iRBD) and patients with RBD associated with Parkinson's Disease (PDRBD) 2.099
Association between dopaminergic medications and REM sleep behavior disorder in Parkinson’s disease: a preliminary cohort study 1.734
Does REM sleep behavior disorder change in the progression of Parkinson’s disease? 1.677
Diagnosing REM sleep behavior disorder in Parkinson's disease without a gold standard: a latent-class model study 1.506
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of the 5-Hydroxytryptophan on REM Sleep Behavior Disorder, Levodopa-Induced Motor Complications and Neuropsychiatric Disorders in Idiopathic Parkinson's disease. 1.398
DIAGNOSING REM SLEEP BEHAVIOUR DISORDER IN PARKINSON DISEASE WITHOUT A GOLD STANDARD: A LATENT CLASSES MODELS STUDY 1.361
Does REM Sleep Behavior Disorder Change in the Progression of Parkinson’s Disease? 1.340
REM sleep behavior disorder changes in the progression of Parkinson's disease: a longitudinal study 1.317
Cognitive and Behavioral features of isolated Rem Sleep Bhaviour disorders (IRBD) and RBD associated with Parkinson's disease (PDRBD 1.025
Neurophysiological features of REM sleep Behaviour Disorder (RBD) correlate with cognitive and psycho-behavioral profile 936
Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease 795
Severity of REM sleep without atonia correlates with measures of cognitive impairment and depressive symptoms in REM sleep behaviour disorder 537
Considering REM Sleep Behavior Disorder in the Management of Parkinson's Disease 484
Oligomeric Alpha-Synuclein and STX-1A from Neural-Derived Extracellular Vesicles (NDEVs) as Possible Biomarkers of REM Sleep Behavior Disorder in Parkinson's Disease: A Preliminary Cohort Study 377
Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms 40
Totale 67.581
Categoria #
all - tutte 78.083
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.083


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216.187 0 0 0 0 0 1.759 807 1.044 365 927 951 334
2021/20222.874 290 229 186 143 214 288 281 126 181 297 269 370
2022/20233.611 366 509 495 325 317 280 171 214 215 218 348 153
2023/20243.703 119 129 140 250 356 519 551 253 146 240 460 540
2024/202528.284 12.124 4.952 9.001 692 375 367 409 61 95 63 71 74
2025/2026907 201 73 157 178 152 146 0 0 0 0 0 0
Totale 67.581